Volume 40, Issue 3, Pages (March 2004)

Slides:



Advertisements
Similar presentations
Cholesterol Metabolism By Amr S. Moustafa, M.D.; Ph.D.
Advertisements

Cholesterol synthesis and breakdown Dr. Carolyn K. Suzuki 1.
CHOLESTEROL 10/02-03/07 I.LEARNING OBJECTIVES 1) To identify the structure of cholesterol 2) To outline the synthesis of cholesterol 3) To describe the.
4 th Global Summit on Toxicology Philadelphia, PA, USA Aug , 2015.
A Helping Hand for Cytochrome P450 Enzymes
Oxidants and antioxidants in alcohol-induced liver disease
Ulrich Beuers, Michael Trauner, Peter Jansen, Raoul Poupon 
Volume 2, Issue 4, Pages (October 2005)
Volume 146, Issue 4, Pages (April 2014)
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Laurent L'homme, PhD, David Dombrowicz, PhD 
Obesity, inflammation, and liver cancer
Volume 51, Issue 1, Pages (July 2009)
Oxidants and antioxidants in alcohol-induced liver disease
Volume 52, Issue 3, Pages (March 2010)
Volume 146, Issue 4, Pages (April 2014)
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Thoetchai (Bee) Peeraphatdit, Douglas A. Simonetto, Vijay H. Shah 
Homing in on bile acid physiology
Volume 129, Issue 2, Pages (August 2005)
Signaling molecules as therapeutic targets in allergic diseases
Volume 56, Issue 3, Pages (March 2012)
Nuclear Receptors, RXR, and the Big Bang
Volume 120, Issue 5, Pages (April 2001)
Volume 153, Issue 3, Pages (September 2017)
TNF-α–induced protein 3 (A20): The immunological rheostat
Targeting the FXR Nuclear Receptor to Treat Liver Disease
ChREBP in NASH – A liver transcription factor comes in from the cold
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Targeting the gut-liver axis in liver disease
Volume 49, Issue 1, Pages 4-8 (January 2006)
Signalling pathways in alcohol-induced liver inflammation
Volume 17, Issue 2, Pages (February 2013)
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Volume 24, Issue 1, Pages (July 2016)
Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate
Volume 13, Issue 8, Pages (November 2015)
The Liver at the Nexus of Host-Microbial Interactions
Pathways of liver injury in alcoholic liver disease
Emina Halilbasic, Thierry Claudel, Michael Trauner 
Volume 57, Issue 5, Pages (November 2012)
Another Shp on the Horizon for Bile Acids
Met as a therapeutic target in HCC: Facts and hopes
Tyrosinase: A Central Regulatory Protein for Cutaneous Pigmentation
Volume 93, Issue 5, Pages (May 1998)
Modulation of inflammation by chondroitin sulfate
The genetics of alcohol dependence and alcohol-related liver disease
Chronic Diarrhea Due to Excessive Bile Acid Synthesis and Not Defective Ileal Transport: A New Syndrome of Defective Fibroblast Growth Factor 19 Release 
Volume 17, Issue 6, Pages (June 2013)
Karel J. van Erpecum, Frank G. Schaap  Journal of Hepatology 
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
Volume 62, Issue 6, Pages (June 2015)
Figure 3 Bile acid-induced hepatic inflammation and carcinogenesis
Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System  Thomas Siegmund Postler, Sankar Ghosh  Cell Metabolism 
Volume 21, Issue 2, Pages (February 2015)
Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa.
Volume 40, Issue 1, Pages (January 2004)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease  Michal Pawlak,
Cytokine Signaling Modules in Inflammatory Responses
Apoptosis: Current Biology
Volume 54, Issue 6, Pages (June 2011)
Foxa1 and Foxa2 regulate bile duct development in mice
Figure 2 Signalling downstream of the IL-6 receptor
Nuclear receptor regulation of hepatic function
Homing in on bile acid physiology
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
Figure 1 Bile acid biosynthesis, transport and metabolism
Unlikely partners in weight loss?
Presentation transcript:

Volume 40, Issue 3, Pages 539-551 (March 2004) Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms  John Y.L Chiang  Journal of Hepatology  Volume 40, Issue 3, Pages 539-551 (March 2004) DOI: 10.1016/j.jhep.2003.11.006

Fig. 1 Bile acid biosynthetic pathways. The classic pathway of bile acid biosynthesis is only present in hepatocytes. The alternative pathway exists in all tissues. Only major regulatory steps and enzymes are shown. The classic pathway synthesizes two primary bile acids, cholic acid and chenodeoxycholic acid. Oxysterols produced in the peripherial tissues may be transported to hepatocytes and converted to CDCA and CA. Primary bile acids are conjugated with glycine or taurine and excreted into the digestive system. Some conjugated bile acids are de-conjugated and converted to the secondary bile acids (damaged), deoxycholic acid and lithocholic acid, by 7α-dehydroxylase in intestinal bacterial flora. CDCA is converted to muricholic acids in the mouse and ursodeoxycholic acid in the bear. See text for detail description and abbreviation list for acronyms. Journal of Hepatology 2004 40, 539-551DOI: (10.1016/j.jhep.2003.11.006)

Fig. 2 Nuclear receptor regulation of the genes involved in bile acid metabolism, reverse cholesterol transport, cholesterol metabolism, triglyceride metabolism and drug metabolism. Target genes that are regulated by nuclear receptors, CAR/PXR/VDR, FXR, PPAR and LXR are grouped according to their roles in drug metabolism, bile acid metabolism, reverse cholesterol transport, triglyceride metabolism and cholesterol metabolism. Upward arrows indicate induction and downward arrows indicate suppression of the target genes by each nuclear receptor. See text for detail description and abbreviation list for acronyms. Journal of Hepatology 2004 40, 539-551DOI: (10.1016/j.jhep.2003.11.006)

Fig. 3 Bile acid signaling pathways in bile acid feedback inhibition of CYP7A1 gene transcription. In SHP-dependent pathway, FXR induces SHP, which then inhibits FTF, HNF4α, or PXR trans-activation of the CYP7A1 gene. In SHP independent pathways, bile acids activate protein kinase C (PKC) and inflammatory cytokines (TNFα, and IL-1β), and initiates MAP kinase/JNK pathway. The downstream targets (cJun, HNF4α) of JNK1/2/3 is not certain. FXR also induces FGF19, which binds FGFR4 and activates a signaling pathway led to phosphorylation of JNK. LCA-activated PXR may bind to the BARE and directly inhibit the CYP7A1 gene. See text for detail description and abbreviation list for acronyms. Journal of Hepatology 2004 40, 539-551DOI: (10.1016/j.jhep.2003.11.006)